» Articles » PMID: 32954426

The Mechanistic Role of Alpha-synuclein in the Nucleus: Impaired Nuclear Function Caused by Familial Parkinson's Disease SNCA Mutations

Overview
Journal Hum Mol Genet
Date 2020 Sep 21
PMID 32954426
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Alpha-synuclein SNCA has been implicated in the etiology of Parkinson's disease (PD); however, the normal function of alpha-synuclein protein and the pathway that mediates its pathogenic effect is yet to be discovered. We investigated the mechanistic role of SNCA in the nucleus utilizing isogenic human-induced pluripotent stem cells-derived neurons from PD patients with autosomal dominant mutations, A53T and SNCA-triplication, and their corresponding corrected lines by genome- and epigenome-editing. Comparisons of shape and integrity of the nuclear envelope and its resistance to stresses found that both mutations result in similar nuclear envelope perturbations that were reversed in the isogenic mutation-corrected cells. Further mechanistic studies showed that SNCA mutation has adverse effects on the nucleus by trapping Ras-related nuclear protein (RAN) and preventing it from transporting key nuclear proteins such as, DNMT3A, for maintaining normal nuclear function. For the first time, we proposed that α-syn interacts with RAN and normally functions in the nucleocytoplasmic transport while exerts its pathogenic effect by sequestering RAN. We suggest that defects in the nucleocytoplasmic transport components may be a general pathomechanistic driver of neurodegenerative diseases.

Citing Articles

Recent advances in nanotechnology for Parkinson's disease: diagnosis, treatment, and future perspectives.

Yadav V, Dhanasekaran S, Choudhary N, Nathiya D, Thakur V, Gupta R Front Med (Lausanne). 2025; 12:1535682.

PMID: 39911864 PMC: 11794224. DOI: 10.3389/fmed.2025.1535682.


The Promise of Epigenetic Editing for Treating Brain Disorders.

Gonzalez Molina L, Dolga A, Rots M, Sarno F Subcell Biochem. 2025; 108():111-190.

PMID: 39820862 DOI: 10.1007/978-3-031-75980-2_4.


Biological Amyloids Chemically Damage DNA.

Horvath I, Aning O, Kk S, Rehnberg N, Chawla S, Molin M ACS Chem Neurosci. 2025; 16(3):355-364.

PMID: 39782739 PMC: 11803820. DOI: 10.1021/acschemneuro.4c00461.


Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson's and other related neurodegenerative diseases.

Riaz Z, Richardson G, Jin H, Zenitsky G, Anantharam V, Kanthasamy A Mol Neurodegener. 2024; 19(1):87.

PMID: 39578912 PMC: 11585115. DOI: 10.1186/s13024-024-00774-0.


Nanotechnology and CRISPR/Cas-Mediated Gene Therapy Strategies: Potential Role for Treating Genetic Disorders.

Kaur G, Arora J, Sodhi A, Bhatia S, Batra N Mol Biotechnol. 2024; .

PMID: 39446301 DOI: 10.1007/s12033-024-01301-8.


References
1.
Goedert M, Jakes R, Spillantini M . The Synucleinopathies: Twenty Years On. J Parkinsons Dis. 2017; 7(s1):S51-S69. PMC: 5345650. DOI: 10.3233/JPD-179005. View

2.
Sugeno N, Jackel S, Voigt A, Wassouf Z, Schulze-Hentrich J, Kahle P . α-Synuclein enhances histone H3 lysine-9 dimethylation and H3K9me2-dependent transcriptional responses. Sci Rep. 2016; 6:36328. PMC: 5093762. DOI: 10.1038/srep36328. View

3.
Maroteaux L, Campanelli J, Scheller R . Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988; 8(8):2804-15. PMC: 6569395. View

4.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

5.
Ward M, Taubes A, Chen R, Miller B, Sephton C, Gelfand J . Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J Exp Med. 2014; 211(10):1937-45. PMC: 4172214. DOI: 10.1084/jem.20140214. View